Series - BIO Benefits

Looking for an efficient and effective way to source new partnerships and manage your meetings for JPM Week? This webinar explains how BIO One-on-One Partnering™ can help. Learn about BIO’s onsite meeting space in San Francisco, tips and tricks for using the system, and how to schedule your meetings with different location options. Also, get a look at how you can stay in-the-know about networking and other opportunities during JPM Week.

For more information about BIO Partnering at JPM Week, please visit: https://www.bio.org/events/bio-partnering-jpm

This webinar covers the following: 
- Preview of BIO’s onsite meeting space in San Francisco 
-Partnering best practices & how to schedule your meetings
- Live demo of the partnering system & advanced features
- Intro to BIO and Novateur Ventures’ JPM Week Events Guide mobile app
- Q&A with the host

Quick Links:

1. Copy of today’s slides: PowerPoint Presentation (bio.org)
2. Registration rates & where to register: https://bpjw.bio.org/registration
3. 2024 Participating companies: https://bpjw.bio.org/participating-companies
4. 2024 Participating investors: https://bpjw.bio.org/bio-one-one-partnering/participating-investors
5. Guide to JPM’24 mobile app for iPhone: https://apps.apple.com/mu/app/guide-to-jpm23/id1494244381
6. Guide to JPM’24 mobile app for Android: https://play.google.com/store/apps/details?id=org.novateur.ConferenceGuide
7. Submit your JPM Week event for our mobile app & Dec 12 webinar event list: https://forms.office.com/pages/responsepage.aspx?id=FmEqTcAdB0iptW1DmWAlb-7aiIadk1dGqhpdctNwLzRUM0pDVkYzQVlDTFJTQUJJMVpWTUVPSFUzSi4u
8. Register for the Dec 12^th JPM Networking Webinar: https://www.bio.org/webinars/raising-capital/bios-jpm-week-events-networking-preview

View this conversation highlighting how BIO member companies are leveraging biotechnology innovations to enable advances in climate adaptation, mitigation, and resilience. Hear how diverse feedstocks and manufacturing processes are targeting emission reduction breakthroughs in hard-to-reach sectors. Learn how regulation and policy can better incentivize innovation and be structured to support new and emerging technologies throughout research, development, demonstration, and deployment.

Big4Bio has heard your concerns loud and clear, and their pre-JPM Week/BioWeekSF online webinar, sponsored by BIO (Biotechnology Innovation Organization), is here to provide solutions and insights that will transform your JPM2024 experience. 

The panelists are industry experts who understand your pain points and provided actionable solutions:
– Dawn Bell, PharmD, Founder/Director, Myracle Therapeutics
– Kimberly Ha, Founder & CEO, KKH Advisors
– Chris Garabedian, Chairman & CEO, Xontogeny
– Lindy Fishburne, Managing Partner, Breakout Ventures

and BIO Partnering at JPM Week context from
– Mackensie Vernetti, Vice President, Partnering, Biotechnology Innovation Organization (BIO)

​It's been one year since the passage of the IRA. The Centers for Medicare & Medicaid Services has moved forward implementing the law's various provisions, including the new Medicare negotiation program and the redesign of the Medicare Part D benefit. Learn the latest developments from our panel of experts, including how the IRA is impacting biopharmaceutical companies today. Panelists delve into other important issues beyond the IRA, including new developments in Medicaid, 340B, and the emergence of Prescription Drug Affordability Boards in a number of states.  

Following reauthorization by Congress of the SBIR/STTR Programs in 2022, there are new rules companies should familiarize themselves with concerning required disclosures of foreign affiliations or relationships with foreign countries. In addition to mandating disclosures prior to receiving SBIR awards, companies must also regularly update NIH following any changes to a disclosure. View this webinar organized by the Biotechnology Innovation Organization (BIO) for a comprehensive discussion on how to effectively navigate these new rules as you apply for SBIR awards.

This webinar is co-hosted by the National Institutes of Health (NIH) Seed Office.

With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.

BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below.  The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.

View this important webinar for those invested in the broader biotech industry, "Understanding the Business Implications of Global Access and Benefit Sharing Policies." Tailored for members of BIO and a diverse community of stakeholders, this high-level session focuses on understanding the impact of recent developments in the global policy arena that will affect industry’s access to vital biologic materials and information. These policies have implications for the way industry will need to share the potential benefits that flow from their use of these physical and digital resources worldwide. Through interactive discussions led by seasoned experts across the Biotech ecosystem, explore the intricate relationship between national and global concerns, while uncovering the potential implications for your company. This webinar will equip you with the knowledge and insights essential to thriving in an ever-evolving global biotech landscape for an empowering dialogue that promises to shape the future of biotechnology.

The BIO Investor Forum is back! Join us at the Hilton San Francisco Union Square from October 17-18 for two days of thought-leadership, partnering, and insight into investment trends and the priorities of venture-stage growth and emerging public biotech companies.

View this webinar to learn more about what’s happening this year, including a half-day pre-conference event, the BIO Seed-Stage Spotlight on Tech Transfer with 34 fast pitches from start-ups outlining their drug development programs.  This webinar will detail what the BIO One-on-One Partnering™ system can do for your business goals and how to use the system's powerful features.  Explore the program, networking opportunities, partnering system fundamentals, gain insight into best practices for partnering, and more.

For more information and to register for the BIO Investor Forum, please visit: https://www.bio.org/events/bio-investor-forum

Register now for the conference to get access to the partnering system and to request your meetings.

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.

Moderator:
– Anne-Virginie Eggimann, Tessera

Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)

Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals